
Commercializing Biomedical Research: How to Finance | Seminar Series
Wolstein Research Building Auditorium, Rm. 1413
2103 Cornell Road Rm. 1413, Cleveland, OH 44106, United States
View MapRegistration
Details
Lewis has over 20 years of executive experience and a history of success in the pharmaceutical and finance industries in both the US and internationally. He co-founded Aegerion Pharmaceuticals, a biopharmaceutical company, and served as its President and COO. In 2012, Lewis joined Insmed, a global biopharmaceutical company that develops and brings to market therapies for patients with serious and rare diseases, where he serves as CEO and Chairman.
In June of 2020, Will joined us to share his career journey, experience in entrepreneurship, and how the COVID-19 crisis impacts the pharmaceutical industry and the advancement of new treatments in medicine. You can watch his previous talk here.
This session will be offered in-person in the Biomedical Research Building Room 105 and via zoom.
The next session in the series will be held Oct. 14 at 8:30 a.m.
Where
Wolstein Research Building Auditorium, Rm. 1413
2103 Cornell Road Rm. 1413, Cleveland, OH 44106, United States
Speakers

Will Lewis
Chairman & CEO
Insmed
https://www.linkedin.com/in/will-lewis-aa89161a8/
Will joined Insmed in 2012 as President and Chief Executive Officer and as a member of the board of directors. He became chair of the board of directors in November 2018. Will is the former Co-Founder, President, and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), and previously spent more than 10 years working in investment banking in the U.S. and Europe. He also previously worked for the U.S. government. Will holds a Bachelor of Arts degree cum laude from Oberlin College as well as a Master of Business Administration and a Juris Doctor with Honors from Case Western Reserve University. Will serves as the chair of the board of trustees of BioNJ, the life sciences association for New Jersey. Will is a member of the board of trustees of Case Western Reserve University as well as a member of the board of the Helix Acquisition Corp.